Document is current

Any future updates will be listed below

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Crossref DOI link: https://doi.org/10.1186/s12931-019-0985-2

Published Online: 2019-01-28

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark